Skip to main content
. Author manuscript; available in PMC: 2024 Jul 14.
Published in final edited form as: ACS Infect Dis. 2023 Jun 30;9(7):1372–1386. doi: 10.1021/acsinfecdis.3c00125

Figure 1. Practical motivations for systematic analyses of drug resistance mutations in SARS-CoV-2 Mpro.

Figure 1.

(A) Comprehensive maps of drug resistance can enable a sequence-informed choice of inhibitors for effective treatments. (B) Potential to identify inhibitors with orthogonal mutational profiles that could be utilized in combination to reduce the likelihood of resistance evolution. (C) A viral passaging study 19 of SARS-CoV-2 reports multiple mutations observed once, suggesting that sampling is insufficient to completely reveal all potential resistance mutations. Comprehensive analyses of resistance potential will likely be of use in efforts to survey for evolution of resistance in patient isolates.